StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

Analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Monday. The brokerage set a “hold” rating on the medical research company’s stock.

A number of other equities research analysts have also weighed in on CTSO. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a report on Tuesday, February 25th. HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Cytosorbents presently has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Performance

CTSO opened at $1.00 on Monday. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.61. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The firm has a market capitalization of $54.68 million, a price-to-earnings ratio of -2.78 and a beta of 0.78. The company’s 50 day moving average price is $1.05 and its two-hundred day moving average price is $1.04.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CTSO. Sargent Investment Group LLC lifted its position in shares of Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after purchasing an additional 192,747 shares during the period. Geode Capital Management LLC lifted its position in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares during the period. Skylands Capital LLC lifted its position in shares of Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after purchasing an additional 26,195 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Cytosorbents in the 4th quarter worth approximately $99,000. Finally, Renaissance Technologies LLC lifted its position in shares of Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.